company background image
GH logo

Guardant Health NasdaqGS:GH Stock Report

Last Price

US$18.73

Market Cap

US$2.4b

7D

-17.3%

1Y

-36.2%

Updated

28 Feb, 2024

Data

Company Financials +

GH Stock Overview

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally.

GH fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Guardant Health, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Guardant Health
Historical stock prices
Current Share PriceUS$18.73
52 Week HighUS$41.06
52 Week LowUS$18.70
Beta0.98
1 Month Change-21.99%
3 Month Change-25.59%
1 Year Change-36.21%
3 Year Change-86.97%
5 Year Change-69.76%
Change since IPO-41.83%

Recent News & Updates

With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Jan 21
With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Recent updates

With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Jan 21
With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Nov 20
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Sep 26
Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)

Sep 05
A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)

Is Guardant Health (NASDAQ:GH) A Risky Investment?

Aug 15
Is Guardant Health (NASDAQ:GH) A Risky Investment?

A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)

May 28
A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Apr 05
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Is Guardant Health (NASDAQ:GH) Using Too Much Debt?

Dec 28
Is Guardant Health (NASDAQ:GH) Using Too Much Debt?

Guardant: Saving Lives One Blood Test At A Time

Oct 16

Here's Why Guardant Health (NASDAQ:GH) Can Afford Some Debt

Aug 15
Here's Why Guardant Health (NASDAQ:GH) Can Afford Some Debt

Guardant Health's test gets FDA win for companion diagnostic to Enhertu's expanded use in lung cancer

Aug 12

Guardant Health: Recent Developments Signal More Upsides

Jul 31

Guardant Health: Pending Recession, May Hurt Cancer Care Demand

Jul 14

Guardant Health (NASDAQ:GH) Is Carrying A Fair Bit Of Debt

Apr 29
Guardant Health (NASDAQ:GH) Is Carrying A Fair Bit Of Debt

Guardant Health: Leaping Growth With Epic

Apr 14

Shareholder Returns

GHUS HealthcareUS Market
7D-17.3%-0.4%2.1%
1Y-36.2%5.7%26.0%

Return vs Industry: GH underperformed the US Healthcare industry which returned 5.7% over the past year.

Return vs Market: GH underperformed the US Market which returned 26% over the past year.

Price Volatility

Is GH's price volatile compared to industry and market?
GH volatility
GH Average Weekly Movement8.5%
Healthcare Industry Average Movement7.1%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: GH's share price has been volatile over the past 3 months.

Volatility Over Time: GH's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20111,774Helmy Eltoukhyhttps://guardanthealth.com

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection.

Guardant Health, Inc. Fundamentals Summary

How do Guardant Health's earnings and revenue compare to its market cap?
GH fundamental statistics
Market capUS$2.38b
Earnings (TTM)-US$479.45m
Revenue (TTM)US$563.95m

4.0x

P/S Ratio

-4.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GH income statement (TTM)
RevenueUS$563.95m
Cost of RevenueUS$227.05m
Gross ProfitUS$336.90m
Other ExpensesUS$816.35m
Earnings-US$479.45m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-3.94
Gross Margin59.74%
Net Profit Margin-85.02%
Debt/Equity Ratio718.4%

How did GH perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.